Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $54.70 USD
Change Today +0.28 / 0.51%
Volume 11.6M
MRK On Other Exchanges
Symbol
Exchange
New York
EN Paris
Sao Paulo
Frankfurt
As of 3:46 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$55.28
Previous Close
$54.42
Day High
$55.40
Day Low
$53.64
52 Week High
01/13/15 - $63.62
52 Week Low
08/24/15 - $45.69
Market Cap
153.3B
Average Volume 10 Days
15.3M
EPS TTM
$1.77
Shares Outstanding
2.8B
EX-Date
09/11/15
P/E TM
30.7x
Dividend
$1.80
Dividend Yield
3.33%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.

68,805 Employees
Last Reported Date: 08/6/15
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (MRK) Key Developments

Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors

Merck and The University of Texas MD Anderson Cancer Center announced that they have entered into a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel antitumor medicines. Under the terms of the agreement, collaborative studies will be conducted in the following tumor types: gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, and hepatocellular carcinoma -- over the three year period of the collaboration. The first studies are scheduled to start enrolling later 2015. The agreement aims to define what combination modalities will work best with KEYTRUDA in these types of tumors by exploring promising new alternatives. The studies will be conducted in parallel, in order to determine optimal regimens in the most efficient manner possible.

Mercks Announces Interim Results from Phase 3 Study of Ebola Vaccine

Merck announced that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100% efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line in The Lancet. The authors report that vaccine efficacy was 100% (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination. To date, more than 4,000 participants have received the vaccine in this innovative trial, called Ebola suffit or Ebola, thats enough. The trial was conducted by a team that included researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and M?decins sans Frontires, among others.

Merck Announces Executive Changes

Merck announced that Isabel De Paoli, currently Head of Group Strategy, has been appointed Head of Group Communications effective March 9, 2016. In her new role, she will be responsible for all global communications at Merck. Walter Huber, who currently holds the position, will retire following the Group's annual earnings press conference on March 8, 2016. On August 1, 2015, Isabel De Paoli will hand over operational responsibility for Group Strategy, which since the beginning of the year has also included Group Organization, to Heiko Schon. Isabel De Paoli will use the time until March to prepare for her new role. Isabel De Paoli joined Merck in August 2006 as Business Development Manager Chemicals and was appointed Head of Strategic Planning Oncology in 2009.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $54.70 USD +0.28

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $143.42 USD +0.70
Allergan plc $311.83 USD +5.85
Amgen Inc $154.22 USD +0.2399
Bayer AG €121.20 EUR +1.89
Gilead Sciences Inc $107.53 USD +0.57
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 15.9x
Price/Sales 3.8x
Price/Book 3.3x
Price/Cash Flow 15.6x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.